↓ Skip to main content

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors

Overview of attention for article published in Investigational New Drugs, February 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

patent
12 patents
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
95 Dimensions

Readers on

mendeley
97 Mendeley
Title
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
Published in
Investigational New Drugs, February 2012
DOI 10.1007/s10637-012-9801-2
Pubmed ID
Authors

Christina M. Annunziata, Elise C. Kohn, Patricia LoRusso, Nicole D. Houston, Robert L. Coleman, Manuela Buzoianu, Gabriel Robbie, Robert Lechleider

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 97 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 1%
United States 1 1%
France 1 1%
Belgium 1 1%
Unknown 93 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 34 35%
Student > Ph. D. Student 12 12%
Other 11 11%
Student > Master 9 9%
Student > Bachelor 4 4%
Other 10 10%
Unknown 17 18%
Readers by discipline Count As %
Agricultural and Biological Sciences 19 20%
Medicine and Dentistry 14 14%
Biochemistry, Genetics and Molecular Biology 13 13%
Pharmacology, Toxicology and Pharmaceutical Science 10 10%
Chemistry 9 9%
Other 13 13%
Unknown 19 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 February 2024.
All research outputs
#2,800,732
of 25,006,193 outputs
Outputs from Investigational New Drugs
#64
of 1,253 outputs
Outputs of similar age
#16,194
of 160,541 outputs
Outputs of similar age from Investigational New Drugs
#3
of 10 outputs
Altmetric has tracked 25,006,193 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,253 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 160,541 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 7 of them.